0.00
0.00%
Close of 6 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Calithera Biosciences
Its shares trade under the ticker CALA. It has been listed since 2 October 2014. In the fiscal year to 31 December 2021, it reported revenue of $9.8m and a net loss of $115.1m. At that date it held total assets of $64.8m and shareholders' equity of $8.4m.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California. The company went IPO on 2014-10-02. The firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The company is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The firm's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Oct 2014
- Employees
- 94
- Website
- calithera.com ↗
Leadership
Pay as last reported
- Dr. Susan MolineauxPresident, Chief Executive Officer, Co-Founder, Director, since 2010$817,299
- Ms. Stephanie WongChief Financial Officer, Secretary$821,324
- Dr. Emil KuriakoseChief Medical Officer$585,448
- Dr. Deepika PakianathanLead Independent Director$91,805
- Dr. Keith OrfordDirector, since 2015$60,425
- Dr. Sunil AgarwalIndependent Director$64,595
- Mr. Scott GarlandIndependent Director$62,454
- Ms. Suzy JonesIndependent Director$55,305
- Mr. Blake WiseIndependent Director$54,454
- Mr. H. Ward WolffIndependent Director$57,954
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 44
- Social
- 31
- Governance
- 43
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Calithera Biosciences focuses on clinical-stage biopharmaceuticals targeting tumor metabolic pathways in South San Francisco.
- CB-839 and CB-1158 are selective inhibitors for glutaminase and arginase enzymes in oncology.
- The company employs 94 full-time staff with a focus on innovative cancer therapies in the Health Care sector.
Weaknesses
- Calithera Biosciences has limited product candidates with only CB-839 and CB-1158 in development.
- The company's reliance on a single lead product candidate CB-839 for oncology treatments.
- Calithera Biosciences has a small employee count of 94, potentially limiting R&D capacity.
Opportunities
- Expanding CB-1158 for hematology and oncology indications in the US market.
- Developing new metabolic pathway inhibitors for tumor microenvironment applications.
- Leveraging clinical-stage biopharmaceutical expertise to attract partnerships in Health Care.
Threats
- Competition from established biotech firms in the US Health Care sector.
- Regulatory challenges for clinical-stage biopharmaceuticals in the US market.
- Potential delays in CB-839 and CB-1158 development timelines affecting market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.